Atypical (nontuberculous) mycobacterial infections

[1]

Classification

[1]

Atypical (nontuberculous) mycobacteria (NTM) are classified by growth rate in culture — the most practical division for dermatology:[1][2][9]

Slow growers (>7 days to culture positivity)

• Mycobacterium marinum — commonest cutaneous NTM; grows at 30-32°C (not 37°C); aquatic exposure.
• Mycobacterium ulcerans — Buruli ulcer; produces mycolactone toxin.
• Mycobacterium avium-intracellulare complex (MAC) — usually pulmonary; cutaneous in immunosuppressed.
• Mycobacterium kansasii — photochromogen; pulmonary; rarely cutaneous.
• Mycobacterium haemophilum — requires iron-supplemented media (hemin/ferric ammonium citrate); immunosuppressed. [1]

Rapid growers ( less than 7 days; often 3-7 days)

• Mycobacterium abscessus complex (subsp. abscessus, massiliense, bolletii) — post-procedure; intrinsic macrolide resistance (erm41 gene).
• Mycobacterium fortuitum group — post-trauma/wounds; more antibiotic-susceptible.
• Mycobacterium chelonae — disseminated cutaneous disease in immunosuppressed (corticosteroids).[6][8]

Pathophysiology

NTM are ubiquitous in the environment (water, soil, dust, biofilms in plumbing). Infection occurs via:[1][2]

• Direct inoculation through broken skin (minor trauma, abrasions, bites, tattoos, injections, surgery).
• Aquatic exposure — fish tanks, swimming pools, marine/brackish water (M. marinum).
• Iatrogenic — contaminated instruments, injectable solutions, mesotherapy, liposuction, catheter sites (M. abscessus, M. fortuitum, M. chelonae).[6]
• Disseminated disease in immunosuppressed (HIV, transplant, anti-TNF) — MAC, M. haemophilum, M. chelonae.[2]

The immune response produces suppurative and/or granulomatous inflammation (caseating or non-caseating). M. ulcerans is unique — its mycolactone toxin causes direct tissue necrosis and immune suppression (explains the painless, destructive ulcer).[2]

[1]

Clinical Features by Species [1]

Mycobacterium marinum ("fish tank / swimming pool granuloma")

• Commonest cutaneous NTM. Aquatic exposure (fish tanks, aquariums, swimming pools, marine/brackish water, fish handling) + minor trauma.[3][5]
• Incubation: 2-3 weeks (range 1-8 weeks).
• Presentation: solitary verrucous nodule or plaque on a finger/hand (dominant hand); may ulcerate. Sporotrichoid (lymphocutaneous) spread — linear chain of nodules along lymphatic drainage up the arm (25-50% of cases).[3]
• Deep infection: tenosynovitis, osteomyelitis, arthritis (if deep inoculation).
• Culture grows at 30-32°C (NOT 37°C — crucial laboratory clue; cultures at 37°C may be negative).[3]
• Treatment: clarithromycin + ethambutol for 3-4 months (first-line); alternatives: doxycycline, minocycline, rifampicin + ethambutol, TMP-SMX. Surgical excision/debridement for deep tenosynovitis/osteomyelitis.[4][5]

Mycobacterium ulcerans (Buruli / Bairnsdale / Daintree ulcer)

• Endemic: West Africa (Benin, Ghana, Côte d'Ivoire), Australia (Victoria), Papua New Guinea, parts of SE Asia.[2]
• Pathogenesis: mycolactone — a polyketide-derived macrolide toxin that causes tissue necrosis and suppresses local immune responses (macrophage apoptosis, cytokine suppression).[2]
• Presentation: starts as a painless subcutaneous nodule, papule, plaque, or oedema → progresses to a large ulcer with characteristic UNDERMINED edges (necrosis extends subcutaneously, larger than the surface opening). Ulcers can be very large and destructive (skin, fat, even bone). Systemic symptoms absent.[2]
• Stages: (1) pre-ulcerative nodule/plaque/oedema; (2) ulcerative (undermined edges); (3) fibrosis/contracture/scarring (healing, but with disability/contracture).
• Treatment: WHO first-line: rifampicin + clarithromycin (or rifampicin + streptomycin/amikacin) for 8 weeks; surgery (debridement, skin grafting) for advanced/fibrotic lesions. Antibiotic therapy has replaced surgery as primary treatment.[2]
• BCG gives partial protection (not a treatment; epidemiological observation).

Mycobacterium abscessus complex

• Rapid grower (culture positive in 3-7 days). Post-procedural — injections, mesotherapy, liposuction, surgery, tattoos, piercing, catheter-related.[6][8]
• Presentation: multiple erythematous nodules, papules, pustules, abscesses or draining sinus tracts weeks to months after the procedure. Often clustered along the procedural track.[6]
• Intrinsic antibiotic resistance: the erm(41) gene confers inducible macrolide resistance in M. abscessus subsp. abscessus (but NOT in subsp. massiliense, which has a non-functional erm41). Subspecies identification is essential for predicting macrolide susceptibility.[8]
• Treatment: amikacin + imipenem or cefoxitin + macrolide (if susceptible based on erm41/ subspecies); prolonged (6+ months); surgical excision often needed for localised disease.[6][8]
• Pulmonary disease: significant pathogen in cystic fibrosis and chronic lung disease.[7][8]

Mycobacterium fortuitum group

• Rapid grower. Post-trauma (wounds, lacerations), catheter-related, postsurgical, tattoo-related.[6]
• Similar to M. abscessus but typically smaller abscesses and more antibiotic-susceptible.
• Treatment: amikacin + fluoroquinolones (ciprofloxacin, moxifloxacin) or doxycycline or TMP-SMX for 4-6 months.[6]

Mycobacterium chelonae

• Rapid grower. Post-procedure or disseminated cutaneous disease in immunosuppressed (especially chronic corticosteroid use).[6]
• Multiple violaceous nodules/abscesses on extremities.
• Treatment: tobramycin + clarithromycin + imipenem or linezolid; surgical excision for localised lesions.[6]

Mycobacterium haemophilum

• Requires iron-supplemented media (hemin or ferric ammonium citrate) and 30°C incubation — easily missed if not specifically requested.[1]
• Immunosuppressed (transplant, HIV, anti-TNF): tender violaceous papules/nodules/ulcers on extremities.

Mycobacterium avium-intracellulare complex (MAC)

• Primarily pulmonary (chronic cough). Cutaneous disease rare; occurs in immunosuppressed (advanced HIV with CD4 less than 50; transplant).[2]
• Prophylaxis in HIV: azithromycin when CD4 less than 50.[2]

Histopathology

• Mixed suppurative and granulomatous inflammation — neutrophils + epithelioid granulomas ± necrosis (caseating or non-caseating).[2][10]
• AFB stain (Ziehl-Neelsen / Fite) may reveal organisms, but sensitivity is variable (organisms may be scant). M. ulcerans lesions show extensive necrosis with clumps of extracellular AFB in the fat.[2]
• Histology alone cannot speciate NTM — requires culture and/or molecular methods.

Investigations and Diagnosis

• Tissue biopsy (deep, including subcutaneous fat) for:
  • AFB stain (Ziehl-Neelsen or Fite-Faraco).
  • Culture at multiple temperatures (30°C AND 37°C) on Lowenstein-Jensen/Middlebrook agar; specify request for NTM — slow growers >7 days, rapid growers less than 7 days.[1][3]
  • Molecular speciation: PCR, line probe assay (GenoType Mycobacterium), or 16S rRNA gene sequencing (gold standard for definitive speciation).[2]
  • Histopathology.
• M. marinum cultures must be incubated at 30-32°C (37°C is usually negative).
• M. haemophilum requires iron-supplemented media (hemin/ferric ammonium citrate) and 30°C.
• M. abscessus subspecies identification (abscessus vs massiliense vs bolletii) via erm(41) gene sequencing — determines macrolide susceptibility.[8]
• Antibiotic susceptibility testing — essential for all NTM; resistance patterns differ markedly from M. tuberculosis and between NTM species.

Differential Diagnosis

• Sporotrichosis (sporotrichoid spread — identical pattern; differentiate by culture/histology).
• Cutaneous tuberculosis (lupus vulgaris, scrofuloderma, warty TB — caseating granulomas; AFB stain; positive Mantoux/IGRA; response to RHZE).
• Leishmaniasis (amastigotes on Giemsa; travel history).
• Staphylococcal/streptococcal abscesses (acute onset; Gram stain).
• Foreign-body granuloma (suture, silica, tattoo ink — polarised light).
• Sarcoidosis (non-caseating "naked" granulomas; systemic features).[10]
• Pyoderma gangrenosum (undermined ulcer; rapidly progressive; associated systemic disease).

Management

[1]

Principles

• Species-specific — always identify the organism (culture/PCR/16S sequencing).[1]
• Susceptibility-guided — antibiotic choices based on in vitro susceptibility (NTM resistance patterns differ from TB and between species).[7]
• Combination therapy (≥2 active drugs) to prevent resistance — monotherapy is never acceptable.[7]
• Duration: typically 3-6+ months depending on species, severity, and immune status.
• Surgical excision/debridement for localised, deep, or treatment-resistant lesions (tenosynovitis, osteomyelitis).
• NTM does NOT respond to standard anti-TB therapy (RHZE) — a common exam and clinical pitfall.[1][7]

Species-specific regimens

Prognosis

• Most cutaneous NTM infections respond well to appropriate therapy (if species is correctly identified and treatment is susceptibility-guided).
• M. abscessus is the most difficult to treat (intrinsic resistance; prolonged therapy; surgical excision often required).[8]
• M. ulcerans can cause significant morbidity (contracture, disability) if treatment is delayed.
• Disseminated disease (immunosuppressed) carries worse prognosis.[2]

Exam Pearls

[1] [1] [1] [1]

Red Flags

Exam application bank (NEET-PG / INICET)

One-line answer

Atypical (nontuberculous, NTM) mycobacteria are environmental organisms (water, soil) causing cutaneous and soft-tissue infections — usually after trauma, aquatic exposure, or iatrogenic procedures. Classified by growth rate: slow growers (M. marinum — 'fish tank granuloma', grows at 30°C, sporotrichoid spread; M. ulcerans — Buruli ulcer, mycolactone toxin, painless undermined ulcers) and rapid growers (M. abscessus complex — post-procedure, erm41 macrolide resistance; M. fortuitum group; M. chelonae). M. marinum is the commonest cutaneous NTM (aquatic exposure, clarithromycin + ethambutol). M. ulcerans causes Buruli ulcer (mycolactone toxin, WHO first-line rifampicin + clarithromycin). Diagnosis: tissue biopsy for AFB + culture at 30°C AND 37°C + PCR/16S sequencing for speciation. Treatment is species-specific, based on susceptibility testing, with ≥2 active drugs (never monotherapy — r

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Atypical (nontuberculous) mycobacterial infections.

Expanded exam teaching (depth pass)

Clinical reasoning

For Atypical (nontuberculous) mycobacterial infections, examiners test whether you can prioritise life threats, choose the right first test, and give specific therapy (agent, dose, route, timing). Generic phrases without numbers score poorly.

Mechanism → feature map

Build a short chain: cause → pathophysiologic intermediate → clinical feature → complication. Every major symptom in the classic vignette should sit on that chain.

Investigation strategy

• Bedside/first-line tests that change immediate management
• Confirmatory or staging tests
• What a normal result does not exclude
• When not to delay treatment for imaging (unstable patient)

Management ladder

1. Resuscitation / ABC / sepsis or haemorrhage bundle as relevant
2. Specific antidote / procedure / antimicrobial / reperfusion / surgery
3. Supportive care and monitoring targets
4. Definitive long-term therapy and secondary prevention
5. Disposition and safety-net advice

Special populations

Always prepare one line each for children, pregnancy, elderly, renal/hepatic impairment, and immunocompromised patients when the topic allows.

Pitfalls that fail candidates

• Treating the number not the patient
• Missing pregnancy status when relevant
• Imaging before stabilisation
• Wrong empiric cover or wrong antidote timing
• Incomplete counselling on recurrence, adherence, or red-flag return

Atypical (nontuberculous, NTM) mycobacteria are environmental organisms (water, soil) causing cutaneous and soft-tissue infections — usually after trauma, aquatic exposure, or iatrogenic procedures. Classified by growth rate: slow growers (M. marinum — 'fish tank granuloma', grows at 30°C, sporotrichoid spread; M. ulcerans — Buruli ulcer, mycolactone toxin, painless undermined ulcers) and rapid growers (M. abscessus complex — post-procedure, erm41 macrolide resistance; M. fortuitum group; M. che [1]

[1] [1]

References

1. [1]Gonzalez-Santiago TM, Drage LA. Nontuberculous Mycobacteria: Skin and Soft Tissue Infections Dermatol Clin, 2015.PMID 26143432
2. [2]Franco-Paredes C, Marcos LA, Henao-Martínez AF, et al. Cutaneous Mycobacterial Infections Clin Microbiol Rev, 2018.PMID 30429139
3. [3]Aubry A, Mougari F, Reibel F, et al. Mycobacterium marinum Microbiol Spectr, 2017.PMID 28387180
4. [4]Medel-Plaza M, Esteban J. Current treatment options for Mycobacterium marinum cutaneous infections Expert Opin Pharmacother, 2023.PMID 37145964
5. [5]Tsiolakkis G, Liontos A, Filippas-Ntekouan S, et al. Mycobacterium marinum: A Case-Based Narrative Review of Diagnosis and Management Microorganisms, 2023.PMID 37512971
6. [6]Sepulcri C, Vena A, Bassetti M. Skin and soft tissue infections due to rapidly growing mycobacteria Curr Opin Infect Dis, 2023.PMID 36718980
7. [7]Lange C, Böttger EC, Cambau E, et al. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases Lancet Infect Dis, 2022.PMID 35090639
8. [8]Cristancho-Rojas C, Varley CD, Lara SC, et al. Epidemiology of Mycobacterium abscessus Clin Microbiol Infect, 2024.PMID 37778416
9. [9]Emmerich K, Fabri M. [Nontuberculous mycobacteria] Hautarzt, 2017.PMID 28331949
10. [10]Terziroli Beretta-Piccoli B, Mainetti C, Peeters MA, et al. Cutaneous Granulomatosis: a Comprehensive Review Clin Rev Allergy Immunol, 2018.PMID 29352388